

**VIRBAC EXERCISES ITS OPTION FOR A COMMERCIAL LICENCE AGREEMENT
TO USE VIVALIS' EBx[®] PLATFORM
FOR THE PRODUCTION OF SEVERAL VACCINES.**

Nantes (France) – April 1st, 2008 – VIVALIS (EURONEXT : VLS) announces today that VIRBAC has exercised its option for a commercial license to use VIVALIS' EBx[®] platform for the production of companion animal vaccines.

« We are pleased to reach this new milestone in the collaboration with VIRBAC, one of the first independent companies exclusively dedicated to animal health. This agreement with VIRBAC confirms the growing interest of pharmaceutical industry for EBx[®] cellular platform for the production of biological products, either vaccines or therapeutic proteins » said Franck Grimaud, Président du Directoire de VIVALIS.

The licence is world-wide and non-exclusive. The financial terms of the agreement, which remain confidential, include milestone payments and royalties.

**Next calendar:
April 16th, 2008 - Quarterly report: 1st quarter 2008**

About VIVALIS (www.vivalis.com)

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS's expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licences for its EBx[®] embryonic stem cell lines to pharmaceutical and biotechnology companies for the production of viral vaccines.
2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licences its EBx[®] embryonic stem cell lines for the production of recombinant proteins to biotechnology and pharmaceutical companies.
3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established numerous partnerships with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Kaketsuken, Merial and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster of competitive excellence.

Euronext Paris Compartment C - FR0004056851
Reuters: **VLS.PA** – Bloomberg: **VLS FP**

Investor relations:
VIVALIS

Franck Grimaud, C.E.O.
Email: investors@vivalis.com

NewCap

Financial Communication Agency
Steve Grobet / Emmanuel Huynh
Tel.: +33 (0) 1 44 71 94 91 Email: vivalis@newcap.fr